Ortqvist A, Jönsson B, Baltussen R, Ament A
Infektionskliniken, Karolinska sjukhuset, Stockholm.
Lakartidningen. 2000 Nov 8;97(45):5120-5.
The pneumococcal vaccine has been shown to be about 70 percent efficacious in preventing invasive pneumococcal disease in elderly persons. In a European multicenter study, pneumococcal vaccination was moderately cost-effective in preventing hospital admission due to invasive pneumococcal disease in persons 65 years of age or above. In Sweden the cost was approximately 300,000 SEK per quality adjusted life years (QALY) gained, but only about 60,000 SEK per QALY in a two-way sensitivity analysis making reasonable assumptions regarding the incidence and mortality of invasive pneumococcal disease in this age group. On the basis of these findings, pneumococcal vaccination should be recommended for all persons 65 years of age or older.
肺炎球菌疫苗已被证明在预防老年人侵袭性肺炎球菌疾病方面约有70%的疗效。在一项欧洲多中心研究中，肺炎球菌疫苗接种在预防65岁及以上人群因侵袭性肺炎球菌疾病而住院方面具有一定的成本效益。在瑞典，每获得一个质量调整生命年（QALY）的成本约为300,000瑞典克朗，但在一项双向敏感性分析中，基于对该年龄组侵袭性肺炎球菌疾病的发病率和死亡率做出合理假设，每QALY的成本仅约为60,000瑞典克朗。基于这些发现，应建议所有65岁及以上的人接种肺炎球菌疫苗。
